title: Who will benefit from combination therapy? The role of 5 alpha reductase inhibitors and alpha blockade: a reflection from MTOPS.
abstract: OBJECTIVE
  The purpose of this review is to revisit the medical treatment of benign prostatic hyperplasia in the light of the most recent data concerning the association of alpha-blockers and 5alpha-reductase inhibitors. Combining these two drugs is not a new concept in treating benign prostatic hyperplasia patients. Alpha blockers are believed to improve symptoms and flow rate by inducing relaxation of the smooth muscle neck and prostate area (dynamic component), while 5alpha-reductase inhibitors are believed to improve symptoms and flow rate by shrinking the transition zone of the prostate through hormonal mechanisms (static component). The proof of this concept, however, could not be clinically demonstrated up until now. The design of previous studies investigating combination therapy with the 5alpha-reductase inhibitor finasteride has been questionable.
  
  
  RESULTS
  Extrapolated from the Medical Therapy of Prostatic Symptoms (MTOPS) study, not yet fully published, again raises the question of the effectiveness of such a combination. There is now some evidence to suggest that combining alpha-blockers and finasteride may be more effective in relieving and preventing the progression of symptoms than either of the two drugs alone.
  
  
  CONCLUSIONS
  Patients most likely to benefit from combination therapy are those in whom baseline risk of progression is significantly higher, generally patients with larger glands and higher prostatic specific antigen values.
authors.affiliation: Hospital of Saint-Louis, Paris, France. francois.desgrandchamps@sls.ap-hop-paris.fr
authors.forename: François
authors.initials: F
authors.lastname: Desgrandchamps
mesh_terms: D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase / Q000627:therapeutic use; D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists / Q000009:adverse effects / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D000369:Aged, 80 and over; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D011470:Prostatic Hyperplasia / Q000175:diagnosis* / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D012720:Severity of Illness Index; D016896:Treatment Outcome; D014563:Urodynamics
chemical_list: D058891:5-alpha Reductase Inhibitors; D000317:Adrenergic alpha-Antagonists; D013741:3-Oxo-5-alpha-Steroid 4-Dehydrogenase